Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The company patent portfolio for Tianjin Jianli Technology R & D Co. Ltd. is currently active within the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action across the entire portfolio, which is being handled by a distinct examiner. This indicates a narrow and specific point of contact within the patent office for the company's current legal proceedings. The prosecution is localized within 1 distinct art unit, reflecting a focused technological scope for the pending matter.
SHELTON, SYNPHANE LA'SHAWN serves as the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This single examiner is responsible for the entirety of the company's current pending office actions, concentrating the immediate legal outcomes into a single review process. The Biotechnology & Pharmaceuticals application is being evaluated within a specific technical group. SHELTON, SYNPHANE LA'SHAWN is the primary individual whose decisions will shape the portfolio's near-term results.
Practitioners should note that with only 1 distinct examiner and 1 distinct art unit involved, the portfolio's current momentum is tied to a specific examination environment. This concentration simplifies the tracking of examiner behavior and art unit trends for the pending Biotechnology & Pharmaceuticals application. The 1 pending office action requires a targeted response that addresses the specific concerns of the assigned examiner. This centralized structure reduces the complexity of managing multiple simultaneous patent office interactions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHELTON, SYNPHANE LA'SHAWN | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18647098 | PREPARATION METHOD AND USE OF YAK HIDE-DERIVED OLIGOPEPTIDE FERROUS CHELATE WITH HIGH ANTIOXIDANT ACTIVITY | SHELTON, SYNPHANE LA'SHAWN | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647098 | PREPARATION METHOD AND USE OF YAK HIDE-DERIVED OLIGOPEPTIDE FERROUS CHELATE WITH HIGH ANTIOXIDANT ACTIVITY | SHELTON, SYNPHANE LA'SHAWN | 1652 | §103§112Other | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial